CJC / IPA Blend

The CJC-1295/Ipamorelin blend combines two peptides that stimulate pituitary GH release through distinct, complementary receptor systems. CJC-1295 (Modified GRF 1-29) activates GHRH receptors (GHRH-R) via the cAMP/PKA intracellular pathway. Ipamorelin activates GHSR-1a (ghrelin receptors) via the PLC/IP3 pathway. Because these are separate receptor populations using different second messenger systems, simultaneous activation produces additive-to-synergistic GH pulse amplification without receptor competition or off-target hormone effects.

Both ipamorelin and GHRP-6 are GHSR-1a agonists, but ipamorelin is significantly more selective. GHRP-6 co-elevates cortisol, ACTH, and prolactin — stress and pituitary hormones that confound research readouts. Ipamorelin produces comparable GH stimulation without these side effects (Raun et al. 1998). For research protocols requiring isolated study of GH/IGF-1 axis effects, the CJC-1295/Ipamorelin combination provides cleaner data by eliminating cortisol and prolactin as variables.

Pulsatile GH secretion means GH is released in discrete bursts rather than a steady continuous stream. Endogenously, this occurs 6–12 times per day, with the largest pulses during slow-wave sleep. The pulsatile pattern is important because GH receptor sensitivity, downstream IGF-1 production, and metabolic effects all depend on the pulse amplitude and inter-pulse interval. CJC-1295/Ipamorelin preserves this pulsatile architecture (due to short half-lives) — making it a tool for studying GH pulse physiology rather than pharmacological continuous GH replacement.

Direct combination studies have not been published in the peer-reviewed literature. The scientific rationale for the combination is derived from: (1) Ipamorelin pharmacology demonstrating GHSR-1a selective GH stimulation (Raun et al. 1998); (2) CJC-1295 clinical trial data showing GHRH-R-mediated GH/IGF-1 elevation (Teichman et al. JCEM 2006); and (3) preclinical studies demonstrating additive GH responses when GHRH and GH secretagogues are co-administered, reviewed by Muller et al. (1999).

No. Neither CJC-1295 without DAC nor ipamorelin is FDA-approved for any indication, and the combination has no regulatory approval. Both are research compounds classified as not intended for human therapeutic use. This blend is sold exclusively for in vitro research purposes.

The lyophilized powder blend should be stored at -20°C for long-term stability. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 30 days. Avoid repeated freeze-thaw cycles. Both components maintain stability in lyophilized form; CJC-1295 is relatively more sensitive to DPP-IV degradation in solution due to the absence of albumin binding.